JP2007504159A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504159A5 JP2007504159A5 JP2006524903A JP2006524903A JP2007504159A5 JP 2007504159 A5 JP2007504159 A5 JP 2007504159A5 JP 2006524903 A JP2006524903 A JP 2006524903A JP 2006524903 A JP2006524903 A JP 2006524903A JP 2007504159 A5 JP2007504159 A5 JP 2007504159A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- halo
- alkyl
- carrier
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000001475 halogen functional group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49853203P | 2003-08-28 | 2003-08-28 | |
| PCT/US2004/027997 WO2005039486A2 (en) | 2003-08-28 | 2004-08-27 | Compounds and compositions as protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007504159A JP2007504159A (ja) | 2007-03-01 |
| JP2007504159A5 true JP2007504159A5 (cg-RX-API-DMAC7.html) | 2007-10-11 |
Family
ID=34519982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006524903A Pending JP2007504159A (ja) | 2003-08-28 | 2004-08-27 | プロテインキナーゼ阻害剤としての化合物および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7338957B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1658290A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007504159A (cg-RX-API-DMAC7.html) |
| CN (1) | CN100439365C (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004283093B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0414049A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2536535A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA06002347A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005039486A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0202873D0 (en) | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
| TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| RU2411242C2 (ru) * | 2005-05-13 | 2011-02-10 | Айрм, Ллк. | Соединения и композиции в качестве ингибиторов протеинкиназ |
| GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
| US9074180B2 (en) * | 2006-03-30 | 2015-07-07 | The University Court Of The University Of Edinburgh | Culture medium containing kinase inhibitors, and uses thereof |
| KR20090023561A (ko) | 2006-04-07 | 2009-03-05 | 노파르티스 아게 | ａ) 피리미딜아미노벤즈아미드 화합물과 ｂ) Ｔｈｒ３１５Ｉｌｅ 키나제 억제제를 포함하는 조합물 |
| WO2008147831A1 (en) * | 2007-05-23 | 2008-12-04 | Smithkline Beecham Corporation | Anthranilamides |
| WO2009042013A1 (en) | 2007-08-02 | 2009-04-02 | Millennium Pharmaceuticals, Inc. | Process for the synthesis of e1 activating enzyme inhibitors |
| EP2188292B1 (en) * | 2007-08-08 | 2013-05-29 | GlaxoSmithKline Intellectual Property Development Limited | 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer |
| JP5779778B2 (ja) * | 2007-11-28 | 2015-09-16 | ダナ−ファーバー キャンサー インスティテュート インク．Ｄａｎａ−Ｆａｒｂｅｒ Ｃａｎｃｅｒ Ｉｎｓｔｉｔｕｔｅ， Ｉｎｃ． | Ｂｃｒ−ａｂｌの低分子のミリスチン酸エステル阻害剤及びその使用方法 |
| EP2231282A1 (en) * | 2008-01-22 | 2010-09-29 | Merck Patent GmbH | Protein kinase inhibitors and use thereof |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| PL2300013T5 (pl) | 2008-05-21 | 2025-04-28 | Takeda Pharmaceutical Company Limited | Pochodne fosforu jako inhibitor kinazy |
| NZ596470A (en) | 2009-05-14 | 2014-04-30 | Millennium Pharm Inc | Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate |
| US8728763B2 (en) | 2009-08-11 | 2014-05-20 | Response Genetics | Methods, primers, probes and kits useful for the detection of BRAF mutations |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| CN104876879B (zh) * | 2015-04-14 | 2018-05-18 | 中国科学院合肥物质科学研究院 | 一种bcr-abl激酶抑制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE247469T1 (de) * | 1995-06-07 | 2003-09-15 | Pfizer | Heterocyclische kondensierte pyrimidin-derivate |
| HUP0200403A3 (en) * | 1998-09-18 | 2004-07-28 | Abbott Gmbh & Co Kg | Pyrrolopyrimidines as protein kinase inhibitors, pharmaceutical compositions containing them and their use |
| ES2245955T3 (es) * | 1999-12-21 | 2006-02-01 | Sugen, Inc. | 7-aza-indolin-2-onas 4-sustituidas y su utilizacion como inhibidores de proteina-quinasa. |
| UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| US20040235867A1 (en) * | 2001-07-24 | 2004-11-25 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
-
2004
- 2004-08-26 US US10/927,992 patent/US7338957B2/en not_active Expired - Fee Related
- 2004-08-27 EP EP04816834A patent/EP1658290A4/en not_active Withdrawn
- 2004-08-27 JP JP2006524903A patent/JP2007504159A/ja active Pending
- 2004-08-27 MX MXPA06002347A patent/MXPA06002347A/es active IP Right Grant
- 2004-08-27 WO PCT/US2004/027997 patent/WO2005039486A2/en not_active Ceased
- 2004-08-27 CN CNB2004800245751A patent/CN100439365C/zh not_active Expired - Fee Related
- 2004-08-27 AU AU2004283093A patent/AU2004283093B2/en not_active Ceased
- 2004-08-27 CA CA002536535A patent/CA2536535A1/en not_active Abandoned
- 2004-08-27 BR BRPI0414049-4A patent/BRPI0414049A/pt not_active IP Right Cessation
-
2008
- 2008-01-07 US US11/970,278 patent/US20080108616A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007504159A5 (cg-RX-API-DMAC7.html) | ||
| JP2009532360A5 (cg-RX-API-DMAC7.html) | ||
| US12090139B2 (en) | Formulations comprising triptan compounds | |
| ES2213775T3 (es) | Metodos de lucha contra las enfermedades infecciosas utilizando bis-benzimidazol dicationicos. | |
| ES2802175T3 (es) | Tieno [3,2-d]pirimidinas, furo[3,2,d]pirimidinas y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones del virus sincitial respiratorio | |
| JP2012523415A5 (cg-RX-API-DMAC7.html) | ||
| NO20062713L (no) | 2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister | |
| JP2001526218A5 (cg-RX-API-DMAC7.html) | ||
| JP2003509349A5 (cg-RX-API-DMAC7.html) | ||
| WO2010136474A3 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| JP2006524222A5 (cg-RX-API-DMAC7.html) | ||
| JP2009521494A5 (cg-RX-API-DMAC7.html) | ||
| EE200300403A (et) | N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina | |
| BR112020008850A2 (pt) | composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3 | |
| BRPI0511504A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides | |
| WO2004052847A3 (en) | Tricyclic steroid hormone nuclear receptor modulators | |
| JP2010510233A5 (cg-RX-API-DMAC7.html) | ||
| KR20200039029A (ko) | 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물 | |
| JP2018526391A5 (cg-RX-API-DMAC7.html) | ||
| CA2671470A1 (en) | Powder formulation for valganciclovir | |
| ES2262689T3 (es) | Composicion que contiene un antagonista del receptor de angiotensina ii y un diuretico y su uso para el tratamiento de la hipertension. | |
| RU2002100058A (ru) | Кристаллические производные 1-метилкарбапенема | |
| HU211666A9 (en) | Antiviral compounds | |
| HRP20110938T1 (hr) | Spojevi koji sadrže gvanidin i koji se koriste kao agonisti muskarinskih receptora | |
| JP2013518036A5 (cg-RX-API-DMAC7.html) |